CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nexus Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nexus Biopharma Inc
8 Hillside Ave
Suite 108
Phone: (973) 524-6100p:973 524-6100 Montclair, NJ  07042  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Nexus Biopharma, Inc., formerly Plata Resources, Inc., is engaged in developing a weight loss drug that activates the 5' adenosine monophosphate-activated protein kinase (AMPK) metabolic pathway. The Company is developing a treatment for obesity. It has worked for the virtual screening, assay development and optimization, compound selection and screening, and active-to-hit work to support hit identification of inhibitors of Fyn kinase. It is also focused on developing a drug for the blood chemistry improvements for type 2 diabetes. The Company has completed pre-clinical trials of the pharmaceutical activation of AMPK metabolic pathway. The Company focuses on advancing these to pre-Investigational New Drug (IND) trials in preparation for the United States Food and Drug Administration (FDA) human trials of a drug.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
5/31/20172/28/2017YesYes---

Industries
SIC Code Description
1000 Metal mining
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Chief Financial Officer, Secretary, Director Warren C.Lau 63 6/9/2016 6/9/2016

Business Names
Business Name
NEXS
Nexus BioPharma, Inc.
PTAE

General Information
Outstanding Shares: 64,309,656 (As of 5/31/2017)
Shareholders: 35
Stock Exchange: OTC
Federal Tax Id: 753267338


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023